|
**Overview**: Leukemia AML Characterization Panel**Introduction**: The Leukemia AML Characterization Panel is a diagnostic tool designed to characterize acute myeloid leukemia using whole blood or bone marrow samples. In India, AML affects ~2-3 per 100,000 adults, with heterogeneous prognosis based on immunophenotype (CD34+, CD117+, CD13+, CD33+) and molecular markers. High morbidity from under-characterization in rural/low-SES patients with blasts or cytopenias, limited labs, delayed risk-adapted therapy (intensive chemo, HSCT) leading to relapse or toxicity. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs flow cytometry and PCR for 33 AML markers (CD34, CD117, CD13, CD33, MPO, HLA-DR, CD15, etc.) over 1-2 days with high accuracy, valuable for confirming myeloid lineage and subtype (M0-M7 FAB/WHO). This diagnostic falls under leukemia screening and targets patients with suspected AML, addressing accurate detection to guide induction (7+3), targeted therapy (IDH/FLT3 inhibitors), or HSCT. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise AML profiling and improving survival. Its blood/bone marrow-based approach ensures reliable marker analysis.**Other Names**: AML Char Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/hematology/oncology/cytogenetics, compliant with 2025 standards.**Historical Milestone**: AML flow/molecular panel standard; in India, used in oncology centers.**Purpose**: The test assesses 33 parameters including AML markers to guide characterization, confirm myeloid lineage, inform risk-adapted therapy.**Test Parameters**: 1â€"33. AML Markers (CD34, CD117, CD13, CD33, etc.).**Pretest Condition**: No fasting required; patients should have blasts or cytopenias.**Specimen**: 3 mL whole blood or bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for flow/PCR).**Medical History**: Patients should provide details on fever, bleeding, organomegaly.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed AML including mortality, benefits of characterization, and minimal discomfort from sampling.**Procedural Considerations**: The test involves sample processing using flow cytometry/PCR by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low blast count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Myeloid marker expression confirms AML subtype, necessitating specialist input.**Specialist Consultation**: Hematologists/oncologists should be consulted for management.**Additional Supporting Tests**: Cytogenetics, NPM1/FLT3 for confirmation.**Test Limitations**: Requires viable blasts; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Leukemia Studies India 2023. |
